Top-News
Gesundheitswesen USA

Immunic News

Aktie
WKN:  A2PHD4 ISIN:  US4525EP1011 US-Symbol:  IMUX
1,195 $
-0,035 $
-2,85%
14.06.24 21:59:42
Handeln Depot/Watchlist
Aktienanzahl *
44,40 Mio.
Marktkapitalisierung *
49,38 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 25.07.2023

Immunic News

28.05.24 - PR Newswire
Immunic to Participate in Industry and Scientific Conferences in June
Immunic to Participate in Industry and Scientific Conferences in June PR Newswire
08.05.24 - PR Newswire
Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update
Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update PR Newswire
06.05.24 - PR Newswire
Immunic to Participate in Investor and Scientific Conferences in May
Immunic to Participate in Investor and Scientific Conferences in May PR Newswire
01.05.24 - PR Newswire
Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update
Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update PR Newswire
30.04.24 - PR Newswire
Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation
Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-​Remitting Multiple Sclerosis in the Peer Reviewed Journal, ...
04.04.24 - PR Newswire
Immunic to Host MS R&D Day and Participate in Investor Conferences in April
Immunic to Host MS R&D Day and Participate in Investor Conferences in April PR Newswire
20.03.24 - PR Newswire
Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States
Immunic Receives Notice of Allowance for Composition-​of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States PR Newswire
07.03.24 - PR Newswire
Immunic to Participate in Investor and Scientific Conferences in March
Immunic to Participate in Investor and Scientific Conferences in March PR Newswire
29.02.24 - PR Newswire
Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024
Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024 PR Newswire
22.02.24 - PR Newswire
Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update
Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update PR Newswire
15.02.24 - PR Newswire
Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update
Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update PR Newswire
01.02.24 - PR Newswire
Immunic to Participate in Investor and Scientific Conferences in February
Immunic to Participate in Investor and Scientific Conferences in February PR Newswire
05.01.24 - 4investors
Immunic: Erfolgreiche Finanzierungsrunde
05.01.24 - PR Newswire
Thinking about buying stock in Quantumscape, Petroleo Brasileiro, Novo Nordisk, AST SpaceMobile, or Immunic?
Thinking about buying stock in Quantumscape, Petroleo Brasileiro, Novo Nordisk, AST SpaceMobile, or Immunic? PR Newswire
05.01.24 - PR Newswire
Immunic Highlights 2023 Accomplishments and Upcoming Milestones
Immunic Highlights 2023 Accomplishments and Upcoming Milestones PR Newswire
05.01.24 - PR Newswire
Immunic, Inc. Announces Private Placement of up to $240 Million
Immunic, Inc. Announces Private Placement of up to $240 Million PR Newswire
21.11.23 - PR Newswire
Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dosing Regimens in Multiple Sclerosis
Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dosing Regimens in Multiple Sclerosis PR Newswire
14.11.23 - PR Newswire
Immunic, Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Immunic, Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Update PR Newswire
07.11.23 - PR Newswire
Immunic to Announce Financial Results for the Third Quarter Ended September 30, 2023, and Provide Corporate Update
Immunic to Announce Financial Results for the Third Quarter Ended September 30, 2023, and Provide Corporate Update PR Newswire
02.11.23 - PR Newswire
Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts
Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts PR Newswire

Newssuche

Videos

13.06.24 -3,86%
Technical Trading: Zukauf-​Chance bei Top-Trade, wenn
Sugar No.11 Long Typ: Turbo Open End WKN: VV50DP Hebel: 5 Laufzeit: OpenEnd Einstieg: prozyklisch ... Mehr »